PI3K Pathway Biomarker Testing in Veterinary Tumors
The PI3K pathway is a signaling cascade involved in cell growth and survival. Aberrations in this pathway are often linked to cancer, including in veterinary medicine where tumors can affect pets as well as their owners. This service offers comprehensive testing for PI3K pathway biomarkers in veterinary tumors. Understanding these markers helps veterinarians tailor more effective treatment plans.
The PI3K/AKT/mTOR signaling network plays a crucial role in regulating cell growth and metabolism. Oncogenic mutations in this pathway can lead to uncontrolled cellular proliferation, which is characteristic of cancerous conditions. Detecting and quantifying these biomarkers allows for early diagnosis and personalized therapy strategies.
Our service uses advanced technology to analyze various samples from veterinary tumors, including blood serum, tissue biopsies, and cell cultures. This approach ensures accurate assessment of the PI3K pathway status in different tumor types across species. The primary focus is on identifying key proteins such as p110α/β isoforms, Akt, mTOR, and downstream targets like p70S6K and GSK-3β.
Our process begins with meticulous sample preparation to ensure the integrity of biomarker expression levels. Following extraction, we employ Western blotting techniques along with other quantitative methods to measure protein levels accurately. Data analysis is performed using statistical software packages that comply with international standards (ISO 17025).
The results provide valuable insights into the PI3K pathway activity in tumors, helping clinicians make informed decisions about treatment options. For instance, patients exhibiting high levels of active AKT might benefit from inhibitors targeting this component of the pathway.
Compliance with rigorous quality control measures ensures reliability and reproducibility of our findings. Our team adheres to strict protocols outlined by relevant international guidelines (ASTM E1792). This service is essential for research labs involved in developing new therapeutic agents or studying disease progression mechanisms.
Industry Applications
- Pet owners seeking detailed information about their pet's health status and potential treatment options.
- Veterinarians interested in personalized medicine approaches based on individual patient profiles.
- Pharmaceutical companies conducting clinical trials for new cancer drugs targeting the PI3K pathway.
- Academic institutions focused on understanding tumor biology and developing novel therapies.
Eurolab Advantages
- Accurate Results: Utilizing state-of-the-art laboratory equipment and experienced personnel guarantees precise measurement of PI3K pathway biomarkers.
- Comprehensive Analysis: We offer a full suite of tests covering all major components of the PI3K signaling network, providing comprehensive data sets for comprehensive analysis.
- Fast Turnaround Times: Our efficient workflow minimizes delays between sample submission and receipt of results, enabling timely interventions if necessary.
- Dedicated Expertise: Our staff includes experts with extensive experience in veterinary oncology who can provide valuable input during consultation sessions.
Use Cases and Application Examples
| Case Study | Tumor Type | Biomarker(s) | Results Obtained | Implications for Treatment |
|---|---|---|---|---|
| Pet Dog with Mammary Gland Tumor | Mammary Adenocarcinoma | p110α, Akt, mTOR | High levels of p110α and low activation of Akt detected. | Treatment focused on inhibiting p110α to prevent tumor growth. |
| Cat with Bladder Tumor | Carcinoma In Situ (CIS) | mTOR, GSK-3β | Increased expression of mTOR and reduced phosphorylation of GSK-3β observed. | Therapy aimed at reducing mTOR activity while promoting GSK-3β activation. |
| Puppy with Brain Tumor | Glioma | p70S6K, Akt | Abnormally high levels of p70S6K and Akt detected. | Treatment plan includes targeted inhibition of both proteins to halt proliferation. |
